PRESS RELEASE. Sciety and Sciety Venture Partners have invested EUR 4,3 million in Pharmability (fd TIRmed), a pharmaceutical company developing a new treatment that challenges the short-term nature of current approaches to atopic dermatitis (eczema). Atopic dermatitis affects millions of people worldwide and represents a billion-dollar market with strong growth. The investment will fund the company’s upcoming Phase Ib trial in patients with atopic dermatitis.
Atopic dermatitis is a chronic, recurring condition affecting up to 20 per cent of children and up to 10 per cent of adults worldwide. The condition impacts quality of life and can cause itching, skin irritation, and sleep disturbances. First-line treatments, typically corticosteroids that require daily application, fail to provide sufficient relief for around 70 per cent of patients. For many, the remaining options come with higher risks—or mean living with persistent symptoms.
The market for atopic dermatitis treatments is currently valued at USD 9.3 billion and is expected to grow by 8–10 per cent annually until 2032.
Pharmability is developing a new topical oligonucleotide-based treatment, applied directly to the skin, aimed at addressing the underlying causes of the condition. In preclinical studies, the treatment demonstrated clear symptom relief lasting up to 15 months after only five applications over a two-week period. Since it is not systemically distributed throughout the body, it has a low side-effect profile, distinguishing it from many current alternatives.
The capital raised through the share issue will be used to complete the company’s toxicology studies, manufacture the drug candidate according to GMP standards, and enable the start of the Phase Ib trial.
The share issue attracted strong investor interest, reflecting the high level of confidence in the company’s technology and strategy.
“Pharmability has the potential to transform the treatment landscape for atopic dermatitis. They combine innovative technology with a strong team and a clear strategy – precisely what we seek in our investments. We look forward to following the company’s journey and supporting them in their continued development,” says Andreas Lindblom, Managing Partner at Sciety.
“This capital injection allows us to take the crucial step into clinical studies and move closer to a future where patients with atopic dermatitis can receive treatment that is both more effective and longer lasting than current alternatives. The need for new therapies is significant, and we are grateful for the strong confidence from Sciety and their network. It gives us the momentum to take the next step in our development,” says Leo Holmgren, CEO of Pharmability.
For more information, contact:
Andreas Lindblom, Managing Partner, Sciety: andreas.lindblom@sciety.se, phone: +46 70 375 73 73.
Leo Holmgren, VD, Pharmability, leo.holmgren@pharmability.com, phone: +46 70 049 18 42
About Pharmability
Pharmability is a biotechnology company developing the next generation of immunomodulatory treatments for autoimmune skin diseases, with a focus on atopic dermatitis (eczema). The company’s drug candidate, TIR-C, is a topical oligonucleotide-based treatment that regulates the immune system and addresses the underlying causes of the disease. Preclinical results demonstrate the treatments potential to provide long-lasting relief and reduce treatment burden. Pharmability is headquartered in Stockholm. For more information, visit pharmability.com and follow Pharmability on LinkedIn.
About Sciety
Sciety is a leading investment company, committed to supporting the growth of innovative life science and health tech companies in the Nordic region. We invest alongside Sciety Venture Partners, comprising family offices and private investors, as well as venture capital firms. Our mission is to enable the full potential of life science innovations, helping to bring breakthroughs in healthcare to people all over the world.
